Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 8/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 7/20 | 0.40 |
| ▸ | GRIA3 | P42263 | 7/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 7/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 2/20 | 0.37 |
| ▸ | RGS12 | O14924 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4407721 | 1.00 | SLC7A5 (0.41) | SLC7A5CYP3A4GRIA2GRIA1GRIA3 | |
| SCHEMBL5292027 | 1.00 | SLC7A5 (0.41) | SLC7A5CYP3A4GRIA2GRIA1GRIA3 | |
| SCHEMBL4408441 | 0.82 | GRM2 (0.43) | GRIA2GRIA1GRIA3GRIA4CYP1A2 | |
| SCHEMBL5741845 | 0.82 | GRM2 (0.43) | GRIA2GRIA1GRIA3GRIA4CYP1A2 | |
| SCHEMBL19489921 | 0.80 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL22680029 | 0.80 | GSR (0.42) | CYP1A2NFKB1ALDH1A1APEX1 | |
| SCHEMBL7402279 | 0.78 | ARG1 (0.39) | ALOX15ALDH1A1 | |
| SCHEMBL18920666 | 0.78 | APAF1 (0.34) | CYP1A2KDM4ELMNAPOLBMAPT | |
| SCHEMBL9291759 | 0.76 | GRIA2 (0.46) | CYP3A4GRIA2PKMHSD17B10USP2 | |
| SCHEMBL9292307 | 0.73 | NOS3 (0.36) | SLC7A5CYP3A4PKMCYP1A2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0552417-B1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-07-07 | — | — | EP | claimed |
| US-5883075-A | HYPOTENSIVE AGENT CYCLIC PEPTIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-03-16 | — | — | US | claimed |
| US-5753619-A | CYCLIC HEPTAPEPTIDES FOR CARDIOVASCULAR DISORDERS | TAKEDA CHEMICAL INSUSTRIES, LTD. (JP) | 1998-05-19 | — | — | US | claimed |
| EP-0815870-A2 | Composition for prohylaxis or treatment of cerebral infarction | Takeda Chemical Industries, Ltd. (JP) | 1998-01-07 | — | — | EP | claimed |
| EP-0528312-B1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-07-16 | — | — | EP | claimed |
| EP-0714909-A1 | Composition for prophylaxis or treatment of pulmonary circulatory diseases | Takeda Chemical Industries, Ltd. (JP) | 1996-06-05 | — | — | EP | claimed |
| EP-0655463-A1 | Cyclic hexapeptides having endothelin antagonistic activity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-31 | — | — | EP | claimed |
| EP-0552417-A1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-07-28 | — | — | EP | claimed |
| EP-0528312-A2 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-02-24 | — | — | EP | claimed |
| US-20020168337-A1 | Sustained-release preparation | TAKADA CHEMICAL INDUSTRIES LTD. | 2002-11-14 | — | — | US | disclosed |
| US-20020058622-A1 | Sustained-release preparation | IGARI YASUTAKA (JP) | 2002-05-16 | — | — | US | disclosed |
| US-6376461-B1 | WATER INSOLUBLE OR SLIGHTLY WATER SOLUBLE POLYVALENT METAL SALT OF A GROWTH HORMONE, AND A BIODEGRADABLE POLYMER; ENDOTHELIN ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-04-23 | — | — | US | disclosed |
| US-6251861-B1 | CYCLO(D-ASP-ASP(R1)-ASP-D-THG(2)-LEU-TRP) DISODIUM SALT, WHERE ASP(R1) IS AN ASPARTIC ACID BETA-4-PHENYLPIPERAZINE AMIDE RESIDUE AND THG(2) IS 2-(2-THIENYL)GLYCINE; ANTI-ENDOTHELIN ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-26 | — | — | US | disclosed |
| US-6147051-A | ANTIISCHEMIC AGENT | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2000-11-14 | — | — | US | disclosed |
| EP-0627929-A1 | INHIBITORS OF THROMBOSIS | CORVAS INTERNATIONAL, INC. (US) | 1994-12-14 | — | — | EP | disclosed |
| EP-0626174-A2 | Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-11-30 | — | — | EP | disclosed |
| WO-1994017817-A1 | INHIBITORS OF THROMBOSIS | CORVAS INTERNATIONAL, INC. (US) | 1994-08-18 | — | — | WO | disclosed |
| WO-1993015756-A1 | INHIBITORS OF THROMBOSIS | CORVAS INTERNATIONAL, INC. (US) | 1993-08-19 | — | — | WO | disclosed |
| EP-0552417-A1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-07-28 | — | — | EP | disclosed |
| EP-0528312-A2 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020168337-A1 | Sustained-release preparation | EDNRA, EDNRB, ORAI1 | SLC7A5 314/4885CYP3A4 4551/4885GRIA2 3196/4885 |
| US-20020058622-A1 | Sustained-release preparation | EDNRA, EDNRB, ORAI1 | SLC7A5 314/4885CYP3A4 4551/4885GRIA2 3196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.